NMI 500

Drug Profile

NMI 500

Alternative Names: NMI-500

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator Nemucore Medical Innovations
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Ovarian cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Jan 2016 Phase-I clinical trials in Breast cancer (Diagnosis) in USA (Parenteral) before January 2016
  • 28 Jan 2016 Phase-I clinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top